Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Short term Debt: 2010-2012

Historic Short term Debt for Iovance Biotherapeutics (IOVA) over the last 2 years, with Sep 2012 value amounting to $7.7 million.

  • Iovance Biotherapeutics' Short term Debt rose 21.73% to $7.7 million in Q3 2012 from the same period last year, while for Sep 2012 it was $7.7 million, marking a year-over-year increase of 21.73%. This contributed to the annual value of $7.9 million for FY2011, which is 901.52% up from last year.
  • As of Q3 2012, Iovance Biotherapeutics' Short term Debt stood at $7.7 million, which was down 12.36% from $8.7 million recorded in Q2 2012.
  • Iovance Biotherapeutics' 5-year Short term Debt high stood at $10.7 million for Q1 2012, and its period low was $792,575 during Q4 2010.
  • In the last 3 years, Iovance Biotherapeutics' Short term Debt had a median value of $7.7 million in 2012 and averaged $6.3 million.
  • Data for Iovance Biotherapeutics' Short term Debt shows a peak YoY skyrocketed of 901.52% (in 2011) over the last 5 years.
  • Iovance Biotherapeutics' Short term Debt (Quarterly) stood at $792,575 in 2010, then soared by 901.52% to $7.9 million in 2011, then grew by 21.73% to $7.7 million in 2012.
  • Its Short term Debt stands at $7.7 million for Q3 2012, versus $8.7 million for Q2 2012 and $10.7 million for Q1 2012.